{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:29:19Z","timestamp":1790375359869,"version":"4.1.0"},"reference-count":212,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.blre.2022.100968","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T20:19:43Z","timestamp":1651868383000},"page":"100968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option"],"prefix":"10.1016","volume":"56","author":[{"given":"Jeffrey H.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Garcia-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2022.100968_bb0005","author":"US Food and Drug Administration"},{"key":"10.1016\/j.blre.2022.100968_bb0010","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2022.100968_bb0015","author":"US Food and Drug Administration"},{"key":"10.1016\/j.blre.2022.100968_bb0020","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2022.100968_bb0025","author":"US Food and Drug Administration"},{"key":"10.1016\/j.blre.2022.100968_bb0030","author":"US Food and Drug Administration"},{"key":"10.1016\/j.blre.2022.100968_bb0035","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2022.100968_bb0040","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2022.100968_bb0045","author":"US Food and Drug Administration"},{"key":"10.1016\/j.blre.2022.100968_bb0050","author":"European Medicines Agency"},{"key":"10.1016\/j.blre.2022.100968_bb0055","author":"US Food and Drug Administration"},{"issue":"16","key":"10.1016\/j.blre.2022.100968_bb0060","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/1078-0432.CCR-15-2791","article-title":"Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy","volume":"22","author":"Thielen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0065","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.blre.2022.100968_bb0070","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/bloodadvances.2018017772","article-title":"Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia","volume":"2","author":"Bouillon","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0075","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0080","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.2217\/fon-2019-0555","article-title":"The role of bosutinib in the treatment of chronic myeloid leukemia","volume":"16","author":"Gambacorti-Passerini","year":"2020","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0085","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100968_bb0090","first-page":"2020","volume":"3","year":"2019","journal-title":"Version"},{"issue":"21","key":"10.1016\/j.blre.2022.100968_bb0095","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0100","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.6004\/jnccn.2020.7627","article-title":"Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?","volume":"18","author":"Garcia-Horton","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.blre.2022.100968_bb0105","doi-asserted-by":"crossref","first-page":"e1811","DOI":"10.1200\/OP.20.00967","article-title":"Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia","volume":"17","author":"Talon","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/hematology.2021000239","article-title":"Lifelong TKI therapy: how to manage cardiovascular and other risks","volume":"2021","author":"Mauro","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"24","key":"10.1016\/j.blre.2022.100968_bb0115","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/bloodadvances.2019000865","article-title":"Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP","volume":"3","author":"Baccarani","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2022.100968_bb0125","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/S2152-2650(21)01246-5","article-title":"Update on Treatment-Free Remission in CML","volume":"21","author":"Atallah","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0130","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14737140.2020.1829483","article-title":"On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?","volume":"20","author":"Stagno","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0135","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.4081\/hr.2020.8950","article-title":"Treatment free remission in chronic myeloid leukemia: Lights and shadows","volume":"12","author":"Molica","year":"2020","journal-title":"Hematol Rep"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080697","article-title":"Treatment-free remission-a new aim in the treatment of chronic myeloid leukemia","volume":"11","author":"Kwa\u015bnik","year":"2021","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","article-title":"Treatment-free remission: the new goal in CML therapy","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2022.100968_bb0150","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia","volume":"10","author":"Annunziata","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100968_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.blre.2022.100968_bb0160","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0165","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2022.100968_bb0170","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.blre.2022.100968_bb0175","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2022.100968_bb0180","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2022.100968_bb0185","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.blre.2022.100968_bb0190","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0195","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2019-128761","article-title":"Long-term outcomes in patients with chronic myeloid leukemia in chronic phase receiving frontline nilotinib versus imatinib: ENESTnd 10-year analysis","volume":"134","author":"Hughes","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0200","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0205","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.blre.2022.100968_bb0220","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2020.38.15_suppl.7549","article-title":"Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: \u22658-y update of a phase I\/II study","volume":"38","author":"Br\u00fcmmendorf","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0225","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0230","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.blre.2022.100968_bb0235","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0240","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0245","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1016\/j.blre.2022.100968_bb0250","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0255","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-137393","article-title":"Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the Bfore trial","volume":"136","author":"Br\u00fcmmendorf","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2022.100968_bb0260","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0265","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.blre.2022.100968_bb0275","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2022.100968_bb0280","volume":"136","author":"Hochhaus","year":"2020","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2022.100968_bb0285","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V128.22.1928.1928","article-title":"Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study","volume":"128","author":"Huang","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0290","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100968_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-133922","article-title":"Efficacy and safety of ponatinib (pon) in patients with chronic-phase chronic myeloid leukemia (CP-CML) Who failed one or more second-generation (2G) tyrosine kinase inhibitors (TKIs): analyses based on PACE and optic","volume":"136","author":"Kantarjian","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0300","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/cncr.32623","article-title":"Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"issue":"Suppl. 15","key":"10.1016\/j.blre.2022.100968_bb0305","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2021.39.15_suppl.7009","article-title":"Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): final 10-year results of a phase 1\/2 study","volume":"39","author":"Gambacorti-Passerini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0310","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cncr.32627","article-title":"Long-term results of frontline dasatinib in chronic myeloid leukemia","volume":"126","author":"Maiti","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0315","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/leu.2015.270","article-title":"Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0320","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-134912","article-title":"Long-term cardiac, vascular, and hypertension safety of bosutinib (BOS) versus imatinib (IMA) for newly diagnosed chronic myeloid leukemia (CML): results from the Bfore trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0325","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/ejh.13608","article-title":"Long-term cardiac, vascular, hypertensive and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy","volume":"106","author":"Cortes","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf","year":"2015","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2022.100968_bb0335","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.blre.2022.100968_bb0340","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0345","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0350","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0355","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia","volume":"145","author":"Cortes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0360","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-020-04018-1","article-title":"Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia","volume":"99","author":"Br\u00fcmmendorf","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0365","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","article-title":"Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia","volume":"36","author":"Trask","year":"2012","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0370","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","article-title":"Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0375","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.31082","article-title":"Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.blre.2022.100968_bb0380","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1182\/blood.V126.23.5166.5166","article-title":"Survey of Qol (quality of life) on Patients Receiving Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Korean CML Working Party Group","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2022.100968_bb0385","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0390","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.31323","article-title":"Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib","volume":"124","author":"Efficace","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0395","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11136-021-02952-9","article-title":"Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors","volume":"31","author":"Nguyen","year":"2021","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0400","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","article-title":"Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy","volume":"34","author":"Efficace","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2022.100968_bb0405","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood.V120.21.4445.4445","article-title":"Clinical and Patient-Reported Outcomes of Dasatinib Therapy in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia","volume":"120","author":"Ionova","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0410","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2016.03.004","article-title":"Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia","volume":"16","author":"Khoury","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0415","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12185-011-0864-1","article-title":"Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis","volume":"93","author":"Kobayashi","year":"2011","journal-title":"Int J Hematol"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100968_bb0420","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.1200\/JCO.2018.36.15_suppl.7062","article-title":"Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome\u2013positive (Ph+) leukemia: Phase 1\/2 study update","volume":"36","author":"Gambacorti-Passerini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0425","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/2045893217733444","article-title":"A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib","volume":"7","author":"Seegobin","year":"2017","journal-title":"Pulm Circ"},{"key":"10.1016\/j.blre.2022.100968_bb0430","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2019-121815","article-title":"Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study","volume":"134","author":"Gjertsen","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0435","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2022.100968_bb0440","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100968_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ddtec.2014.03.003","article-title":"Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"11","author":"Balabanov","year":"2014","journal-title":"Drug Discov Today Technol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0455","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/ejh.13524","article-title":"Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data","volume":"106","author":"Gambacorti-Passerini","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0460","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2022.100968_bb0465","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0470","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141125","article-title":"Real-world effectiveness of first-line (1L) dasatinib versus 1L imatinib in newly diagnosed patients with chronic phase chronic myeloid leukemia (CP-CML)","volume":"136x","author":"Klink","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0480","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.15042","article-title":"Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase","volume":"180","author":"Cony-Makhoul","year":"2018","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.blre.2022.100968_bb0485","doi-asserted-by":"crossref","first-page":"14219","DOI":"10.18632\/oncotarget.24478","article-title":"Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients","volume":"9","author":"Tiribelli","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.blre.2022.100968_bb0490","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.neo.2016.07.005","article-title":"Frontline Dasatinib Treatment in a \u201cReal-Life\u201d Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia","volume":"18","author":"Latagliata","year":"2016","journal-title":"Neoplasia"},{"issue":"22","key":"10.1016\/j.blre.2022.100968_bb0495","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1182\/blood.V128.22.5435.5435","article-title":"The real world use of bosutinib in patients with chronic myeloid leukaemia","volume":"128","author":"Apperley","year":"2016","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0500","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood-2019-127029","article-title":"Bosutinib in the real-life treatment of chronic phase chronic myeloid leukemia (CML) patients aged >65 years resistant\/intolerant to frontline tyrosine-kynase inhibitors","volume":"134","author":"Latagliata","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0505","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-018-3507-2","article-title":"Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients","volume":"98","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Ann Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0510","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1182\/blood-2019-127923","article-title":"Real-life outcomes of ponatinib treatment in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): data from a nationwide Belgian registry","volume":"134","author":"Devos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100968_bb0515","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","article-title":"Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study","volume":"67","author":"Heiblig","year":"2018","journal-title":"Exp Hematol"},{"issue":"9","key":"10.1016\/j.blre.2022.100968_bb0520","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-018-3337-2","article-title":"Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice","volume":"97","author":"Breccia","year":"2018","journal-title":"Ann Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0525","first-page":"2905","article-title":"A real life evaluation of efficacy and safety of ponatinib therapy in CML patients","volume":"130","author":"Luciano","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100968_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106690","article-title":"Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome\u2013positive leukemias","volume":"111","author":"Kota","year":"2021","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030515","article-title":"dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0540","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100968_bb0545","first-page":"318","article-title":"Molecular responses after switching from a standard-dose twice-daily nilotinib regimen to a reduced-dose once-daily schedule in patients with chronic myeloid leukemia: a real life observational study (NILO-RED)","volume":"130","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2022.100968_bb0550","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood-2021-145411","article-title":"First interim analysis of the italian dante study: de-escalation before treatment-free remission in patients with chronic myeloid leukemia treated with first-line nilotinib","volume":"138","author":"Breccia","year":"2021","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2022.100968_bb0555","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.blre.2022.100968_bb0560","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0565","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.repce.2017.10.017","article-title":"New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"38","author":"Almeida","year":"2019","journal-title":"Revista Portuguesa de Cardiologia (English Edition)"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0575","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.htct.2020.04.009","article-title":"Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring","volume":"43","author":"Seguro","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2022.100968_bb0580","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13716","article-title":"Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors","volume":"48","author":"Ross","year":"2018","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0585","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0590","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/1358863X20906868","article-title":"Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors","volume":"25","author":"Kondapalli","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.blre.2022.100968_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.675811","article-title":"Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review","volume":"12","author":"Santoro","year":"2021","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0600","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2013.04.027","article-title":"Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes","volume":"272","author":"Doherty","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"issue":"35","key":"10.1016\/j.blre.2022.100968_bb0605","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0610","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0615","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/toxsci\/kfu215","article-title":"A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity","volume":"143","author":"Talbert","year":"2015","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0620","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.blre.2022.100968_bb0625","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.blre.2022.100968_bb0630","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0635","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","article-title":"The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear","volume":"135","author":"Loren","year":"2015","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0640","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches","volume":"33","author":"Lamore","year":"2020","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0645","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0650","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0655","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"de Lavallade","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2022.100968_bb0660","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.blre.2022.100968_bb0665","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bcp.13508","article-title":"Dasatinib-induced pulmonary arterial hypertension","volume":"84","author":"\u00d6zg\u00fcr Yurtta\u015f","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0670","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019865704","article-title":"EXPRESS: Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors","volume":"9","author":"El-Dabh","year":"2019","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0675","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br J Haematol"},{"issue":"36","key":"10.1016\/j.blre.2022.100968_bb0680","doi-asserted-by":"crossref","first-page":"26077","DOI":"10.1074\/jbc.M705008200","article-title":"Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling","volume":"282","author":"Frasca","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2022.100968_bb0685","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0083-6729(08)00604-3","article-title":"c-Abl and insulin receptor signalling","volume":"80","author":"Genua","year":"2009","journal-title":"Vitam Horm"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0690","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41375-018-0337-0","article-title":"Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts","volume":"33","author":"Sadiq","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0695","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1002\/ajh.25232","article-title":"Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy","volume":"93","author":"Racil","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0700","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.3324\/haematol.2013.086355","article-title":"Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia","volume":"98","author":"Racil","year":"2013","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0705","first-page":"A159","article-title":"OWE-019 Mechanisms of chemotherapy-induced diarrhoea","volume":"67","author":"French","year":"2018","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0710","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/SPC.0b013e32835ec861","article-title":"Mechanisms of TKI-induced diarrhea in cancer patients","volume":"7","author":"Bowen","year":"2013","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.blre.2022.100968_bb0715","doi-asserted-by":"crossref","DOI":"10.1177\/1534735420928493","article-title":"Diarrhea induced by small molecule tyrosine kinase inhibitors compared with chemotherapy: potential role of the microbiome","volume":"19","author":"Secombe","year":"2020","journal-title":"Integr Cancer Ther"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0720","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","article-title":"Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction","volume":"16","author":"Sasaki","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.blre.2022.100968_bb0725","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/cncr.25071","article-title":"Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and\/or renal dysfunction","volume":"116","author":"Tong","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0730","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0735","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20165","article-title":"Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs imatinib among patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0740","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0745","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/cncr.31917","article-title":"The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0750","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JOP.18.00483","article-title":"Oral anticancer therapy: management of drug interactions","volume":"15","author":"Rogala","year":"2019","journal-title":"J Oncol Pract"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0755","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0760","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/ejh.13418","article-title":"Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden","volume":"105","author":"Boons","year":"2020","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0765","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/jcph.1312","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor","volume":"58","author":"Tian","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0770","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.1019","article-title":"Pharmacokinetics of asciminib when taken with imatinib or with food","volume":"11","author":"Hoch","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0775","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.blre.2022.100968_bb0780","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical Pharmacokinetics of Imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0785","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.blre.2022.100968_bb0790","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.12769","article-title":"Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug\u2013drug interaction mediated by P-glycoprotein","author":"Lafaie","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0795","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11239-021-02570-9","article-title":"Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation","volume":"53","author":"Wang","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0800","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12185-021-03144-4","article-title":"Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial","volume":"114","author":"Chuah","year":"2021","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0805","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-018-2594-8","article-title":"Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia","volume":"144","author":"Jiang","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0810","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0815","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474086.2017.1262758","article-title":"How could patient reported outcomes improve patient management in chronic myeloid leukemia?","volume":"10","author":"De Marchi","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0820","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb0825","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0830","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0835","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0840","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3324\/haematol.2020.247767","article-title":"Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity","volume":"106","author":"Lando","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0845","first-page":"1173","article-title":"Fatigue: an overview","volume":"78","author":"Rosenthal","year":"2008","journal-title":"Am Fam Physician"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100968_bb0850","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1200\/JCO.2021.39.15_suppl.7039","article-title":"Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib","volume":"39","author":"Deininger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0855","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","article-title":"De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial","volume":"6","author":"Clark","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2022.100968_bb0860","series-title":"European Hematology Association (EHA25 Virtual)","article-title":"Molecular response by 24 months of nilotinib 300 mg bid treatment in patients with chronic myeloid leukemia (CML) who failed to achieve dmr with imatinib: results from the ENESTpath study","author":"Rea","year":"2020"},{"key":"10.1016\/j.blre.2022.100968_bb0865","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.leukres.2018.02.013","article-title":"Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study","volume":"67","author":"Hiwase","year":"2018","journal-title":"Leuk Res"},{"issue":"article 9","key":"10.1016\/j.blre.2022.100968_bb0870","first-page":"1","article-title":"Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia","volume":"7","author":"Mita","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb0875","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.32504","article-title":"Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"126","author":"Naqvi","year":"2020","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2022.100968_bb0880","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/S2152-2650(20)30815-6","article-title":"Interim analysis from the OPTIC trial - a dose-ranging study of 3 starting doses of ponatinib","volume":"20","author":"Cortes","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100968_bb0885","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2021.39.15_suppl.7000","article-title":"OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)","volume":"39","author":"Cortes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.blre.2022.100968_bb0890","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0895","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb0900","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1038\/s41375-018-0247-1","article-title":"Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?","volume":"32","author":"Aghel","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0905","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ejhf.457","article-title":"Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?","volume":"18","author":"Vaduganathan","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"Suppl. 15","key":"10.1016\/j.blre.2022.100968_bb0910","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1200\/JCO.2020.38.15_suppl.7550","article-title":"An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia","volume":"38","author":"Januzzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0915","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdy019","article-title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"29","author":"Khoury","year":"2018","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.blre.2022.100968_bb0920","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/bloodadvances.2020002644","article-title":"Ponatinib coronary microangiopathy: novel bedside diagnostic approach and management with N-acetylcysteine","volume":"4","author":"Wu","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0925","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000501927","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome-positive acute leukemia: recommendations of a german expert consensus panel with focus on cardiovascular management","volume":"143","author":"Saussele","year":"2020","journal-title":"Acta Haematol"},{"issue":"29","key":"10.1016\/j.blre.2022.100968_bb0930","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0935","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/17512433.2021.1894129","article-title":"Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies","volume":"14","author":"Wang","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.blre.2022.100968_bb0940","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb0945","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0950","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0955","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"issue":"19","key":"10.1016\/j.blre.2022.100968_bb0960","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/cncr.31663","article-title":"Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value","volume":"124","author":"Hidalgo-L\u03ccpez","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb0965","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1038\/bcj.2016.18","article-title":"A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML","volume":"6","author":"Krysiak","year":"2016","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.blre.2022.100968_bb0970","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1002\/cncr.24432","article-title":"Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2022.100968_bb0975","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/cncr.20285","article-title":"Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia","volume":"100","author":"Quintas-Cardama","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb0980","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/ejh.13436","article-title":"Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia","volume":"105","author":"Cesini","year":"2020","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.blre.2022.100968_bb0985","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/cncr.20292","article-title":"Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase","volume":"100","author":"Cortes","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0990","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.leukres.2003.11.003","article-title":"Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia","volume":"28","author":"Ault","year":"2004","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.blre.2022.100968_bb0995","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cncr.23718","article-title":"The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"113","author":"Aribi","year":"2008","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.blre.2022.100968_bb1000","doi-asserted-by":"crossref","first-page":"e18539","DOI":"10.1200\/JCO.2019.37.15_suppl.e18539","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"37","author":"Shoukier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2022.100968_bb1005","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/09537104.2020.1809648","article-title":"Myelofibrosis in ITP and with TPO-RA - time to rethink?","volume":"32","author":"Thachil","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2022.100968_bb1010","author":"National Institute of Diabetes and Digestive and Kidney Diseases"},{"issue":"Suppl","key":"10.1016\/j.blre.2022.100968_bb1015","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.clml.2016.02.027","article-title":"Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia","volume":"16","author":"Hoehn","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.blre.2022.100968_bb1020","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.blre.2022.100968_bb1025","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.blre.2022.100968_bb1030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/pbc.23389","article-title":"Imatinib has adverse effect on growth in children with chronic myeloid leukemia","volume":"59","author":"Bansal","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.blre.2022.100968_bb1035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","article-title":"Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia","volume":"159","author":"Shima","year":"2011","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb1040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/jpet.103.061184","article-title":"Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism","volume":"309","author":"Cataldi","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.blre.2022.100968_bb1045","doi-asserted-by":"crossref","first-page":"48948","DOI":"10.1155\/SRCM\/2006\/48948","article-title":"Relative hypocalcaemia and muscle cramps in patients receiving imatinib for gastrointestinal stromal tumour","volume":"2006","author":"Zekri","year":"2006","journal-title":"Sarcoma"},{"issue":"8","key":"10.1016\/j.blre.2022.100968_bb1050","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/s41375-019-0443-7","article-title":"Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"33","author":"Janssen","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2022.100968_bb1055","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.blre.2022.100968_bb1060","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1002\/cncr.29587","article-title":"Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"121","author":"Yilmaz","year":"2015","journal-title":"Cancer"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:29:47Z","timestamp":1759436987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2200042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":212,"alternative-id":["S0268960X2200042X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100968","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100968"}}